Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Novavax Inc
NVAX | US
10.55
USD0.57
5.71%
NVAX | US
Loading StockChartView...
About Novavax Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
10.55
Open
9.87
High
10.72
Low
9.80
Novavax Inc. a biotechnology company that promotes improved health by discovering developing and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges which is evaluating vaccines for COVID-19 influenza and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine NVX-CoV2373 under the brand names of Nuvaxovid Covovax and Novavax COVID-19 Vaccine Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax Inc. was incorporated in 1987 and is headquartered in Gaithersburg Maryland.
View LessNVAX | US
Risk
87.1
Sharpe
0.38
Luna's Score
46/100
Recommendation
Hold
Luna says (NVAX | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Strong Operating Margin (> 25%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
107.9%1 month
87.1%3 months
80.6%6 months
67.7%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
1.78
Price to book
49.52
Debt to equity
-0.54
Debt to assets
0.13
Ent. to EBITDA
-0.53
Ent. to rev.
1.45
PEG
-
Other Fundamentals
EBITDA
-240.84M
MarketCap
1.69B
MarketCap(USD)
1.69B
Div. yield
-
Op. margin
39.01
Erngs. growth
70.90
Rev. growth
-2.10
Ret. on equity
-898.20
Short ratio
5.19
Short perc.
26.40
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
2.87
Range1M
3.95
Range3M
5.61
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.07
Price X volume
58.69M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.53 | 0.53 | Cheaper |
| Ent. to Revenue | 1.45 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 49.52 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 80.62 | 72.80 | Par |
| Debt to Equity | -0.54 | -1.23 | Expensive |
| Debt to Assets | 0.13 | 0.25 | Cheaper |
| Market Cap | 1.69B | 3.66B | Emerging |
